Sarepta Operating Income from 2010 to 2025

SRPT Stock

USD 73.61 2.72 3.56%

Sarepta Therapeutics Operating Income yearly trend continues to be comparatively stable with very little volatility. Operating Income is likely to outpace its year average in 2025. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Sarepta Therapeutics generates from its operations. View All Fundamentals

Operating Income

First Reported

1996-03-31

Previous Quarter

22.2 M

Current Value

161.7 M

Quarterly Volatility

58.7 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Sarepta Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sarepta Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 39.6 M, Interest Expense of 10.6 M or Selling General Administrative of 585.8 M, as well as many indicators such as Price To Sales Ratio of 5.77, Dividend Yield of 0.0 or PTB Ratio of 6.75. Sarepta financial statements analysis is a perfect complement when working with Sarepta Therapeutics Valuation or Volatility modules.

Check out the analysis of Sarepta Therapeutics Correlation against competitors.

For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.

Latest Sarepta Therapeutics' Operating Income Growth Pattern

Below is the plot of the Operating Income of Sarepta Therapeutics over the last few years. Operating Income is the amount of profit realized from Sarepta Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Sarepta Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Sarepta Therapeutics' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sarepta Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Operating Income

Timeline

Sarepta Operating Income Regression Statistics

	Arithmetic Mean	(199,227,372)
	Geometric Mean	154,941,047
	Coefficient Of Variation	(123.83)
	Mean Deviation	197,118,003
	Median	(171,638,000)
	Standard Deviation	246,699,062
	Sample Variance	60860.4T
	Range	793.1M
	R-Value	(0.13)
	Mean Square Error	64034.1T
	R-Squared	0.02
	Significance	0.62
	Slope	(6,951,199)
	Total Sum of Squares	912906.4T

Sarepta Operating Income History

	2025	229 M
	2024	218.1 M
	2023	-267.8 M
	2022	-536.2 M
	2021	-449.7 M
	2020	-564.2 M
	2019	-522.3 M

Other Fundumenentals of Sarepta Therapeutics

Non Operating Income Net Other

Sarepta Therapeutics Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Property Plant Equipment	Net Receivables	Current Deferred Revenue	Long Term Debt	Short Term Debt	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Short Long Term Debt	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock
Total Assets		0.86	0.27	-0.97	0.92	0.49	0.97	1.0	0.84	-0.29	0.98	0.87	0.9	0.96	0.75	0.54	0.99	0.99	0.93	0.93	0.59	0.92	0.94
Total Stockholder Equity	0.86		0.13	-0.77	0.83	0.3	0.72	0.85	0.88	-0.33	0.81	0.81	0.72	0.71	0.7	0.66	0.82	0.86	0.82	0.77	0.8	0.69	0.75
Net Debt	0.27	0.13		-0.41	0.42	0.71	0.31	0.24	0.39	0.01	0.38	0.47	0.16	0.32	-0.23	-0.28	0.26	0.26	0.24	0.3	0.13	0.15	0.32
Retained Earnings	-0.97	-0.77	-0.41		-0.91	-0.59	-0.97	-0.96	-0.84	0.34	-0.98	-0.86	-0.84	-0.96	-0.66	-0.44	-0.97	-0.97	-0.9	-0.93	-0.47	-0.9	-0.94
Accounts Payable	0.92	0.83	0.42	-0.91		0.37	0.87	0.89	0.9	-0.24	0.94	0.97	0.88	0.82	0.62	0.26	0.89	0.89	0.82	0.91	0.67	0.85	0.92
Short Term Investments	0.49	0.3	0.71	-0.59	0.37		0.53	0.5	0.45	-0.22	0.51	0.33	0.21	0.58	0.18	0.34	0.49	0.52	0.52	0.39	0.04	0.35	0.35
Total Liab	0.97	0.72	0.31	-0.97	0.87	0.53		0.97	0.75	-0.25	0.97	0.82	0.9	0.99	0.71	0.43	0.98	0.96	0.89	0.91	0.45	0.95	0.93
Total Current Assets	1.0	0.85	0.24	-0.96	0.89	0.5	0.97		0.83	-0.3	0.98	0.85	0.89	0.96	0.76	0.57	0.99	0.99	0.93	0.91	0.58	0.92	0.92
Intangible Assets	0.84	0.88	0.39	-0.84	0.9	0.45	0.75	0.83		-0.35	0.83	0.89	0.7	0.71	0.62	0.41	0.81	0.83	0.73	0.81	0.58	0.71	0.79
Common Stock	-0.29	-0.33	0.01	0.34	-0.24	-0.22	-0.25	-0.3	-0.35		-0.28	-0.18	-0.19	-0.25	-0.2	-0.35	-0.26	-0.33	-0.26	-0.21	-0.14	-0.2	-0.2
Property Plant Equipment	0.98	0.81	0.38	-0.98	0.94	0.51	0.97	0.98	0.83	-0.28		0.9	0.9	0.95	0.69	0.43	0.98	0.98	0.92	0.94	0.58	0.92	0.96
Net Receivables	0.87	0.81	0.47	-0.86	0.97	0.33	0.82	0.85	0.89	-0.18	0.9		0.87	0.77	0.54	0.17	0.84	0.84	0.74	0.89	0.71	0.8	0.92
Current Deferred Revenue	0.9	0.72	0.16	-0.84	0.88	0.21	0.9	0.89	0.7	-0.19	0.9	0.87		0.84	0.71	0.26	0.88	0.85	0.75	0.89	0.63	0.94	0.91
Long Term Debt	0.96	0.71	0.32	-0.96	0.82	0.58	0.99	0.96	0.71	-0.25	0.95	0.77	0.84		0.65	0.5	0.98	0.95	0.9	0.87	0.42	0.89	0.91
Short Term Debt	0.75	0.7	-0.23	-0.66	0.62	0.18	0.71	0.76	0.62	-0.2	0.69	0.54	0.71	0.65		0.63	0.74	0.73	0.74	0.71	0.48	0.8	0.64
Net Tangible Assets	0.54	0.66	-0.28	-0.44	0.26	0.34	0.43	0.57	0.41	-0.35	0.43	0.17	0.26	0.5	0.63		0.53	0.59	0.64	0.33	0.35	0.35	0.29
Long Term Debt Total	0.99	0.82	0.26	-0.97	0.89	0.49	0.98	0.99	0.81	-0.26	0.98	0.84	0.88	0.98	0.74	0.53		0.98	0.92	0.92	0.53	0.92	0.94
Capital Surpluse	0.99	0.86	0.26	-0.97	0.89	0.52	0.96	0.99	0.83	-0.33	0.98	0.84	0.85	0.95	0.73	0.59	0.98		0.94	0.9	0.57	0.89	0.92
Short Long Term Debt	0.93	0.82	0.24	-0.9	0.82	0.52	0.89	0.93	0.73	-0.26	0.92	0.74	0.75	0.9	0.74	0.64	0.92	0.94		0.84	0.6	0.81	0.84
Net Invested Capital	0.93	0.77	0.3	-0.93	0.91	0.39	0.91	0.91	0.81	-0.21	0.94	0.89	0.89	0.87	0.71	0.33	0.92	0.9	0.84		0.59	0.95	0.97
Long Term Investments	0.59	0.8	0.13	-0.47	0.67	0.04	0.45	0.58	0.58	-0.14	0.58	0.71	0.63	0.42	0.48	0.35	0.53	0.57	0.6	0.59		0.47	0.54
Net Working Capital	0.92	0.69	0.15	-0.9	0.85	0.35	0.95	0.92	0.71	-0.2	0.92	0.8	0.94	0.89	0.8	0.35	0.92	0.89	0.81	0.95	0.47		0.92
Capital Stock	0.94	0.75	0.32	-0.94	0.92	0.35	0.93	0.92	0.79	-0.2	0.96	0.92	0.91	0.91	0.64	0.29	0.94	0.92	0.84	0.97	0.54	0.92

Click cells to compare fundamentals

About Sarepta Therapeutics Financial Statements

Sarepta Therapeutics shareholders use historical fundamental indicators, such as Operating Income, to determine how well the company is positioned to perform in the future. Although Sarepta Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Sarepta Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Sarepta Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Operating Income	218.1 M	229 M
Non Operating Income Net Other	46.9 M	49.2 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Sarepta Stock Analysis

When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Sarepta Operating Income from 2010 to 2025

Latest Sarepta Therapeutics' Operating Income Growth Pattern

Sarepta Operating Income Regression Statistics

Sarepta Operating Income History

Other Fundumenentals of Sarepta Therapeutics

Sarepta Therapeutics Operating Income component correlations

About Sarepta Therapeutics Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Sarepta Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY